Pfizer Inc. (PFE) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Drug Manufacturers - General
Is Pfizer Inc. a safe investment right now?
Pfizer Inc.'s Altman Z-Score of 2.02 places it in the gray zone. Our fair value estimate is $33.60 (Strong Buy Zone). Moat rating: 2.9/5 stars.
Could Pfizer Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 2.02 places the company in the gray zone (1.8-3.0), warranting closer scrutiny.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives PFE's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.0284 | 1.2 | 0.03 |
| B · Retained Earnings / Total Assets | RE / TA | 0.5506 | 1.4 | 0.77 |
| C · EBIT / Total Assets | EBIT / TA | 0.049 | 3.3 | 0.16 |
| D · Market Cap / Total Liabilities | MCap / TL | 1.2559 | 0.6 | 0.75 |
| E · Revenue / Total Assets | Rev / TA | 0.3006 | 1.0 | 0.3 |
How has PFE's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 2.97 | Gray |
| 2023 | 1.69 | Distress |
| 2024 | 2.01 | Gray |
| 2025 | 2.02 | Gray |
Source: Calculated from PFE's latest 10-K filing on SEC EDGAR.
What is Pfizer Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $2.00 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $1.36 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $2.96 | 27 analysts consensus |
| Trailing P/E | 19.7x | Current market pricing |
| Fair P/E (β discount) | 16.8x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Accelerating | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $28.97 (27 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Pfizer Inc. have a durable competitive advantage?
Moat rating: 2.9/5.
What makes up PFE's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 4/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is PFE's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 27.6% | — |
| 2023 | 2.0% | Declining |
| 2024 | 7.3% | Rising |
| 2025 | 6.8% | Stable |
Source: ROIC calculated from SEC EDGAR filings.
Is Pfizer Inc.'s dividend safe?
Can Pfizer Inc. afford its dividend?
Payout ratio is 126.5%. FCF covers the dividend 2.9x. 55 consecutive years of payments.
Pfizer Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $62.6B | $63.6B | $101.2B | Declining |
| Net Income | $7.8B | $8.0B | $31.4B | Declining |
| Free Cash Flow | $9.1B | $9.8B | $26.0B | Declining |
| Gross Margin | 74.3% | 71.9% | 66.0% | Rising |
Recent events that affect our PFE analysis
PFE earnings report scheduled
Upcoming report. Consensus EPS estimate: $0.72. Revenue estimate: $13.82B. Our current Fair Value: $33.60 — a significant beat or miss could shift this estimate.
PFE analyst consensus: 38% bullish (11 of 29 analysts)
2 Strong Buy, 9 Buy, 15 Hold, 1 Sell, 2 Strong Sell. Consensus target: $28.97 (8.1% upside). Compare with our independent Fair Value: $33.60.
PFE filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
PFE beat EPS estimates by 16.2%
Reported EPS: $0.66 vs estimate $0.57. Earnings strength supports our Fair Value of $33.60 (25.4% above current price).
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE paid $0.4300/share dividend
Dividend Safety Grade: B. Payout ratio: 126.5%.
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE paid $0.4300/share dividend
Dividend Safety Grade: B. Payout ratio: 126.5%.
PFE beat EPS estimates by 37.4%
Reported EPS: $0.87 vs estimate $0.63. Earnings strength supports our Fair Value of $33.60 (25.4% above current price).
PFE filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE beat EPS estimates by 35.9%
Reported EPS: $0.78 vs estimate $0.57. Earnings strength supports our Fair Value of $33.60 (25.4% above current price).
PFE filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE paid $0.4300/share dividend
Dividend Safety Grade: B. Payout ratio: 126.5%.
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE paid $0.4300/share dividend
Dividend Safety Grade: B. Payout ratio: 126.5%.
PFE filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
PFE beat EPS estimates by 36.5%
Reported EPS: $0.92 vs estimate $0.67. Earnings strength supports our Fair Value of $33.60 (25.4% above current price).
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
PFE beat EPS estimates by 37.2%
Reported EPS: $0.63 vs estimate $0.46. Earnings strength supports our Fair Value of $33.60 (25.4% above current price).
PFE filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
PFE paid $0.4300/share dividend
Dividend Safety Grade: B. Payout ratio: 126.5%.
Common questions about Pfizer Inc.
What is Pfizer Inc. stock price today?
Pfizer Inc. (PFE) stock price is $26.80 as of the latest market close, traded on the NYSE exchange.
What does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
What is Pfizer Inc. market cap?
Pfizer Inc. has a market capitalization of $152.45B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is PFE in?
Pfizer Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. It trades on the NYSE under the ticker symbol PFE.
Is PFE stock overvalued or undervalued?
Based on our valuation model, Pfizer Inc. trades 20.2% below our fair value estimate — potentially undervalued.
- FairValueLabs Fair Value: $33.60
- Current Price: $26.80
- Valuation Zone: Strong Buy Zone
What is PFE stock forecast and analyst target price?
Based on 27 Wall Street analysts, the consensus price target for Pfizer Inc. is $28.97, implying upside of 8.1% from the current price.
- Analyst High Target: $36.00
- Analyst Low Target: $25.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Pfizer Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Pfizer Inc.:
- Revenue growth (current year est.): -2.0%
- EPS growth (current year est.): -7.9%
- Revenue growth (next year est.): -4.3%
- EPS growth (next year est.): -5.1%
What are Pfizer Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $62.6B | Declining |
| Net Income | $7.8B | Declining |
| Free Cash Flow | $9.1B | Declining |
| Gross Margin | 74.3% | Rising |
What is PFE's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 19.7x
- Forward P/E (next 12 months est.): 9.5x
- FairValueLabs Fair P/E: 16.8x
How volatile is PFE stock?
Pfizer Inc. has a beta of 0.39, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Pfizer Inc. have?
Pfizer Inc.'s balance sheet shows:
- Total Cash: $13.60B
- Total Debt: $67.65B
- Net Cash Position: $-54.05B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Pfizer Inc.'s free cash flow?
Pfizer Inc. generated $13.43B in trailing twelve-month free cash flow (from $11.70B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Pfizer Inc. pay a dividend, and is it safe?
Yes, Pfizer Inc. pays a regular dividend. Here are the key metrics:
- Dividend Yield: 6.3%
- Payout Ratio: 126.5%
- Consecutive Years Paid: 55
- 5-Year Dividend Growth: -22.7%
- FairValueLabs Safety Grade: B
Is Pfizer Inc. at risk of going bankrupt?
Pfizer Inc.'s Altman Z-Score is 2.02, placing it in the gray zone (1.8–3.0) — some financial uncertainty. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Pfizer Inc. have a durable competitive advantage?
Pfizer Inc. scores 2.9/5 stars (Narrow moat · eroding) in our moat analysis:
- ROIC Stability: 2/5
- Gross Margin Trend: 4/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is PFE's return on equity (ROE)?
Pfizer Inc.'s return on equity is 8.9%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy PFE stock?
PFE shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol PFE
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is PFE a value stock or speculative?
FairValueLabs classifies Pfizer Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Pfizer Inc.?
The current CEO of Pfizer Inc. is Dr. Albert Bourla D.V.M., Ph.D..
What is PFE's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $1.36
- Forward EPS (next 12 months est.): $2.81
- Analyst consensus EPS (this year): $2.96
- Analyst consensus EPS (next year): $2.81
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
PFE analysis methodology: How we calculate fair value, Z-Scores, and moat ratings